Dresden \u00dcniversitesi Hastanesi\u2019nde ger\u00e7ekle\u015ftirilen bir klinik deneme, ileri evre solid t\u00fcm\u00f6rlerin tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir geli\u015fmeye i\u015faret ediyor. Ara\u015ft\u0131rmac\u0131lar, T h\u00fccre resept\u00f6rleri (TCR) ile genetik olarak modifiye edilmi\u015f hastan\u0131n kendi ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini kullanarak kanser h\u00fccrelerine \u00f6zg\u00fc sald\u0131r\u0131lar d\u00fczenleyen yeni bir y\u00f6ntem \u00fczerinde olumlu sonu\u00e7lar elde etti. Konvansiyonel kemoterapi ve ba\u011f\u0131\u015f\u0131kl\u0131k kontrollerini engelleyen ila\u00e7lara diren\u00e7 g\u00f6steren ileri evre kat\u0131 t\u00fcm\u00f6rlerde, bu yenilik\u00e7i yakla\u015f\u0131m\u0131n sa\u011flad\u0131\u011f\u0131 \u00f6zg\u00fcn hedefleme, sa\u011fl\u0131kl\u0131 dokulara zarar vermeden kanseri yok etme potansiyeli ta\u015f\u0131yor. Bu durum, solid t\u00fcm\u00f6r alan\u0131nda uzun s\u00fcredir \u00e7\u00f6z\u00fclemeyen \u00f6nemli bir zorluktan kaynaklanan \u00f6nemli bir geli\u015fme olarak dikkat \u00e7ekiyor.<\/p>\n
Ara\u015ft\u0131rman\u0131n merkezinde yer alan IMA203 adl\u0131 h\u00fccre terapisi, PRAME adl\u0131 t\u00fcm\u00f6rlerde yayg\u0131n olarak y\u00fcksek oranda bulunan peptidi hedef al\u0131yor. PRAME, melanom, over kanseri, sarkomlar ve akci\u011fer kanseri gibi bir\u00e7ok t\u00fcrde g\u00fc\u00e7l\u00fc \u015fekilde eksprese edilirken, sa\u011fl\u0131kl\u0131 h\u00fccrelerde neredeyse hi\u00e7 bulunmamas\u0131 nedeniyle ideal bir hedef olarak de\u011ferlendiriliyor. B\u00f6ylelikle genetik m\u00fchendislikle donat\u0131lan T h\u00fccreleri, kanser h\u00fccrelerini hassas \u015fekilde tan\u0131y\u0131p yok ederken normal dokulara zarar vermemeyi ba\u015far\u0131yor. Bu \u00f6zellik, daha \u00f6nce solid t\u00fcm\u00f6r immunoterapisinde kar\u015f\u0131la\u015f\u0131lan ciddi yan etkilerin \u00f6n\u00fcne ge\u00e7mek bak\u0131m\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor.<\/p>\n
Klinik deneme, standart tedavi se\u00e7eneklerini t\u00fcketmi\u015f ve ileri evre agresif t\u00fcm\u00f6r hastal\u0131\u011f\u0131 bulunan 40 hastay\u0131 kapsad\u0131. Bu hastalar\u0131n \u00e7o\u011fu, daha \u00f6nceki tedavilere yan\u0131t vermemi\u015f veya hastal\u0131\u011f\u0131 ilerleyen ki\u015filerden olu\u015fuyordu. Y\u00fcksek afiniteye sahip TCR\u2019lerin PRAME peptidini tan\u0131mas\u0131 sayesinde modifiye edilen T h\u00fccreleri, t\u00fcm\u00f6r h\u00fccrelerini se\u00e7ici olarak tan\u0131y\u0131p y\u0131kmaya y\u00f6nlendirildi. Bu hassas mekanizma, \u00f6nceki daha genel imm\u00fcnoterapilere k\u0131yasla yan etkilerin minimal d\u00fczeyde kalmas\u0131n\u0131 sa\u011flad\u0131. Dolay\u0131s\u0131yla hastalar\u0131n g\u00fcvenli\u011fi a\u00e7\u0131s\u0131ndan ciddi bir avantaj sa\u011fland\u0131.<\/p>\n
\u00c7al\u0131\u015fmadan elde edilen sonu\u00e7lar, umut verici bir tablo \u00e7iziyor. Tedavi edilen hastalar\u0131n yakla\u015f\u0131k yar\u0131s\u0131nda anlaml\u0131 klinik yan\u0131tlar al\u0131nd\u0131. Bu yan\u0131tlar yaln\u0131zca ge\u00e7ici olmay\u0131p, \u00e7o\u011fu durumda sekiz ay\u0131 a\u015fan kal\u0131c\u0131l\u0131klar g\u00f6sterirken, baz\u0131 hastalarda iki y\u0131l\u0131 ge\u00e7en relaps\u0131zl\u0131k d\u00f6nemleri g\u00f6zlemlendi. Geleneksel kemoterapinin genellikle birka\u00e7 ayl\u0131k s\u0131n\u0131rl\u0131 fayda sa\u011flad\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, bu bulunmalar kanser tedavisinde kal\u0131c\u0131 yan\u0131t sa\u011flama ile ilgili \u00f6nemli bir at\u0131l\u0131m olarak \u00f6ne \u00e7\u0131k\u0131yor.<\/p>\n
IMA203\u2019un g\u00fcvenlik profili de dikkat \u00e7ekici bi\u00e7imde olumlu olarak rapor edildi. Hastalarda \u00e7o\u011funlukla hafif-orta derecede ate\u015f ve deri d\u00f6k\u00fcnt\u00fcleri gibi ge\u00e7ici yan etkiler g\u00f6r\u00fcld\u00fc ve bu durumlar ciddi metabolik veya imm\u00fcnolojik komplikasyonlara yol a\u00e7mad\u0131. \u0130mm\u00fcnolojik kaynakl\u0131 a\u011f\u0131r yan etkilerin yoklu\u011fu, modifiye T h\u00fccrelerinin hedef se\u00e7icili\u011finin ve kontroll\u00fc aktivitesinin g\u00fc\u00e7l\u00fc kan\u0131t\u0131 olarak de\u011ferlendiriliyor. Bu, geni\u015f hastac\u0131 kitlelerine g\u00fcvenle uygulanabilecek bir tedavi se\u00e7ene\u011fi olmas\u0131n\u0131n temelini olu\u015fturuyor.<\/p>\n
Erken Klinik Deneme Birimi Ba\u015fkan\u0131 Prof. Dr. Martin Wermke, elde edilen bulgular\u0131 devrimci olarak tan\u0131ml\u0131yor. \u0130lk defa s\u0131kl\u0131kla g\u00f6r\u00fclen solid t\u00fcm\u00f6rlerde kal\u0131c\u0131 yan\u0131t sa\u011fland\u0131\u011f\u0131n\u0131 belirten Prof. Wermke, tedavi yan\u0131tlar\u0131n\u0131n kapsam\u0131 ve s\u00fcresinin mevcut terapilere k\u0131yasla \u00e7ok daha \u00fcst\u00fcn oldu\u011funu vurgulad\u0131. Baz\u0131 hastalarda potansiyel k\u00fcratif sonu\u00e7lar yakaland\u0131\u011f\u0131n\u0131 ifade eden bilim insan\u0131, bu terapinin tarih boyunca k\u00f6t\u00fc prognoza sahip hastalar i\u00e7in b\u00fcy\u00fck bir umut oldu\u011funu dile getirdi.<\/p>\n
Dresden \u00dcniversitesi Hastanesi\u2019nin h\u00fccre terapileri alan\u0131ndaki uzun y\u0131llara dayanan deneyimi, bu ba\u015far\u0131da kritik rol oynad\u0131. Klinik Direkt\u00f6r Prof. Dr. Martin Bornh\u00e4user, hematolojik kanser tedavilerinde iki dekada yakla\u015fan deneyimin, bu altyap\u0131 ve uzmanl\u0131k sayesinde IMA203 gibi yenilik\u00e7i h\u00fccre terapilerinin solid t\u00fcm\u00f6rlerde uygulanabilirli\u011fini m\u00fcmk\u00fcn k\u0131ld\u0131\u011f\u0131n\u0131 belirtti. Bu geli\u015fme, zorlu solid t\u00fcm\u00f6r alan\u0131nda h\u00fccresel imm\u00fcnoterapilerin \u00f6n\u00fcn\u00fc a\u00e7an \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olarak de\u011ferlendiriliyor.<\/p>\n
Ara\u015ft\u0131rma ekibi \u00f6n\u00fcm\u00fczdeki s\u00fcre\u00e7te, \u00f6zellikle melanom hastalar\u0131nda IMA203\u2019un etkinli\u011fini ve g\u00fcvenli\u011fini daha b\u00fcy\u00fck \u00e7apl\u0131 faz 2 ve faz 3 klinik \u00e7al\u0131\u015fmalarda test etmeyi hedefliyor. Bu alan, konvansiyonel imm\u00fcnoterapilere yan\u0131t vermeyen hastalar i\u00e7in kritik bir tedavi bo\u015flu\u011funu temsil ediyor. Ba\u015far\u0131l\u0131 sonu\u00e7lar\u0131n ard\u0131ndan IMA203\u2019un standart tedavi protokollerine girmesi ve milyonlarca hastan\u0131n ya\u015fam kalitesini y\u00fckseltmesi bekleniyor. NCT\/UCC Dresden\u2019in geni\u015f stratejik vizyonu alt\u0131nda, h\u00fccre bazl\u0131 yeni nesil imm\u00fcnoterapilerle kanser m\u00fccadelesi g\u00fc\u00e7lendiriliyor.<\/p>\n
TU Dresden T\u0131p Fak\u00fcltesi Dekan\u0131 Prof. Dr. Esther Troost, ara\u015ft\u0131rma tak\u0131m\u0131n\u0131n azim ve kararl\u0131l\u0131\u011f\u0131n\u0131 takdirle kar\u015f\u0131lad\u0131. Onkoloji alan\u0131ndaki bilimsel kapasitenin her ge\u00e7en g\u00fcn artt\u0131\u011f\u0131n\u0131 belirten Troost, IMA203\u2019un klinik ba\u015far\u0131lar\u0131n\u0131n, h\u00fccresel imm\u00fcnoterapilere yap\u0131lan yat\u0131r\u0131mlar\u0131n somut sonu\u00e7 verdi\u011finin teyidi oldu\u011funu ifade etti. Bu geli\u015fmeler, s\u0131n\u0131rl\u0131 tedavi se\u00e7eneklerine sahip kanser hastalar\u0131 i\u00e7in umut \u0131\u015f\u0131\u011f\u0131n\u0131n daha da parlakla\u015fmas\u0131n\u0131 sa\u011fl\u0131yor.<\/p>\n
Dresden \u00dcniversitesi Hastanesi Medikal Direkt\u00f6r\u00fc Prof. Dr. Uwe Platzbecker ise benzer h\u00fccre terapilerinin onay s\u00fcre\u00e7lerinin yak\u0131nda tamamlanmas\u0131n\u0131n beklendi\u011fini bildirdi. Hastalar\u0131n bu yenilik\u00e7i tedavilere h\u0131zl\u0131 eri\u015fimini sa\u011flamak i\u00e7in gerekli t\u00fcm haz\u0131rl\u0131klar\u0131n yap\u0131ld\u0131\u011f\u0131n\u0131 belirtti. Bu \u00e7abalar, hastanenin ki\u015fiye \u00f6zel kanser imm\u00fcnoterapisinde \u00f6nc\u00fc merkez olma vizyonunu per\u00e7inliyor.<\/p>\n
IMA203\u2019un \u00e7al\u0131\u015fma prensibi, hastadan al\u0131nan T h\u00fccrelerinin genetik m\u00fchendislik ile PRAME peptidini y\u00fcksek afinite ile tan\u0131yacak T h\u00fccre resept\u00f6rleriyle donat\u0131lmas\u0131d\u0131r. Hastaya tekrar verilen bu modifiye T h\u00fccreleri, dola\u015f\u0131mda t\u00fcm\u00f6r b\u00f6lgelerine y\u00f6nelerek, peptid-HLA komplekslerini tan\u0131r ve sadece kanser h\u00fccrelerine y\u00f6nelik \u00f6ld\u00fcr\u00fcc\u00fc aktivite ba\u015flat\u0131r. Bu y\u00f6ntem, adaptif ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin \u00f6zg\u00fcnl\u00fc\u011f\u00fcn\u00fc, genetik d\u00fczenleme ve h\u00fccre \u00fcretim teknolojilerindeki ilerlemelerle birle\u015ftirerek \u00f6nceki antikora dayal\u0131 yakla\u015f\u0131mlardan farkl\u0131 ve g\u00fc\u00e7l\u00fc bir antit\u00fcm\u00f6r etkisi yarat\u0131yor.<\/p>\n
Ayr\u0131ca bu tedavinin ba\u015far\u0131s\u0131nda, kalitesi standartlara uygun ve hastaya uygulanabilir hale getirilmi\u015f TCR-T h\u00fccre \u00fcr\u00fcnlerinin g\u00fcvenli ve etkin \u00fcretimi sa\u011flayan altyap\u0131n\u0131n \u00f6nemli rol\u00fc bulunuyor. Dresden \u00dcniversitesi Hastanesi\u2019nin h\u00fccre i\u015fleme merkezleri ve multidisipliner i\u015fbirli\u011fi, \u00fcretim lojisti\u011fi ve ruhsatland\u0131rma a\u015famalar\u0131n\u0131 h\u0131zla a\u015farak bu akademik inovasyonun klinik uygulamaya d\u00f6n\u00fc\u015fmesini m\u00fcmk\u00fcn k\u0131ld\u0131. \u0130mm\u00fcnologlar, onkologlar, genetik m\u00fchendisleri ve klinik \u00e7al\u0131\u015fma uzmanlar\u0131n\u0131n yak\u0131n koordinasyonu ba\u015far\u0131n\u0131n temel ta\u015flar\u0131ndan biri oldu.<\/p>\n
Sonu\u00e7 olarak, IMA203 h\u00fccre terapisi, solid t\u00fcm\u00f6rlerin tedavisinde anlaml\u0131 ve uzun s\u00fcreli yan\u0131tlar\u0131n sa\u011flanabilece\u011fini, yan etki profillerinin ise y\u00f6netilebilir d\u00fczeyde oldu\u011funu g\u00f6sterdi. H\u00fccresel imm\u00fcnoterapi alan\u0131nda \u00f6nemli bir paradigm de\u011fi\u015fimi sunan bu geli\u015fmeler, kanser bak\u0131m\u0131nda kal\u0131c\u0131 remisyonlar ve kal\u0131c\u0131 iyile\u015fmeler i\u00e7in umut vadediyor. Dresden \u00dcniversitesi Hastanesi\u2019nden gelen bu sonu\u00e7lar, ki\u015fiye \u00f6zel ve ba\u011f\u0131\u015f\u0131kl\u0131k-temelli kanser tedavilerinin tam potansiyelinin ger\u00e7ekle\u015ftirilmesi yolunda \u00f6nemli bir a\u015famay\u0131 temsil ediyor.<\/p>\n
—<\/p>\n
**Ara\u015ft\u0131rma Konusu**: \u0130nsanlar
\n**Makale Ba\u015fl\u0131\u011f\u0131**: Research success at Dresden University Hospital: New cell therapy shows promising results in advanced tumor diseases
\n**Haberin Yay\u0131n Tarihi**: 25-Apr-2025
\n**Web References**:
\n**Doi Referans**: 10.1038\/s41591-025-03650-6
\n**Resim Credits**: UKD\/Thomas Albrecht
\n**Anahtar Kelimeler**: T cell receptor-engineered T cells, IMA203, PRAME peptide, solid tumors, immunotherapy, melanoma, cell therapy, clinical trial, Dresden University Hospital, personalized cancer treatment, durable response, cancer immunotherapy<\/p>\n","protected":false},"excerpt":{"rendered":"
Dresden \u00dcniversitesi Hastanesi\u2019nde ger\u00e7ekle\u015ftirilen bir klinik deneme, ileri evre solid t\u00fcm\u00f6rlerin tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7an bir geli\u015fmeye i\u015faret ediyor. Ara\u015ft\u0131rmac\u0131lar, T h\u00fccre resept\u00f6rleri (TCR) ile genetik olarak modifiye edilmi\u015f hastan\u0131n kendi ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini kullanarak kanser h\u00fccrelerine \u00f6zg\u00fc sald\u0131r\u0131lar d\u00fczenleyen yeni bir y\u00f6ntem \u00fczerinde olumlu sonu\u00e7lar elde etti. Konvansiyonel kemoterapi ve ba\u011f\u0131\u015f\u0131kl\u0131k kontrollerini engelleyen ila\u00e7lara diren\u00e7 g\u00f6steren…<\/p>\n","protected":false},"author":1,"featured_media":3912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[3307,3306,3310,3309,3308],"tmauthors":[],"class_list":{"0":"post-3911","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-genetik-olarak-modifiye-edilmis-t-hucre-tedavisi","9":"tag-ileri-evre-solid-tumorlerde-hucre-tedavisi","10":"tag-kanserde-uzun-sureli-klinik-yanitlar","11":"tag-kemoterapiye-direncli-kanser-tedavisi","12":"tag-prame-hedefli-kanser-immunoterapisi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Ileri-Evre-Tumorlerde-Hucre-Tedavisi-Basarisi-1745597687.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3911"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3911\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3912"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3911"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}